EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, TVTX: Travere Therapeutics Inc

11 Dec 25 13:29
LAST:

35.25

CHANGE:
 0.87		OPEN:
34.42		HIGH:
35.26		ASK:
0.00		VOLUME:
529.8K
CHG(%):
2.53		PREV:
34.38		LOW:
33.90		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
11 Dec 2534.4235.2633.9035.25529.8K
10 Dec 2534.5135.1533.8434.381.15M
09 Dec 2534.2635.1834.2234.511.18M
08 Dec 2535.6035.7934.0034.291.54M
05 Dec 2535.3235.5934.5235.001.57M
04 Dec 2534.4535.6434.4535.331.43M
03 Dec 2534.4135.3534.1034.851.45M
02 Dec 2535.5035.6433.4533.992.63M
01 Dec 2534.9435.5034.5735.191.29M
28 Nov 2536.8737.5035.3135.41761.3K

PROFILE

Name:Travere Therapeutics Inc
About:Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Sector:Healthcare
Industry:Biotechnology
Address:3611 Valley Centre Drive, San Diego, CA, United States, 92130
Website:https://www.travere.com
CUSIP:89422G107
CIK:0001438533
ISIN:US89422G1076
FIGI:BBG000P9D6W9

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-8.46 
Forward P/E:-28.30 
PEG Ratio:0.10 
Price to Sales:7.09 
Price to Book:42.01 
Profit Margin:-0.20 
Operating Margin:0.15 
Return on Assets:-0.11 
Return on Equity:-4.11 
EPS Ratio:-2.02 
Revenue:435.83M 
Shares:89.14M 
Market Cap:3.142B 

TECHNICAL INDICATORS

MA5:34.651.7%
MA10:34.801.3%
MA20:35.040.6%
MA50:31.6311.5%
MA100:25.7237.1%
MA200:21.4164.7%
STO9:58.89
STO14:30.20
RSI14:52.20
WPR14:-53.30
MTM14:0.36
ROC14:0.01 
ATR:1.38 
Week High:35.791.5%
Week Low:33.844.2%
Month High:37.506.4%
Month Low:33.0564.7%
Year High:37.506.4%
Year Low:12.91173.0%

RECENT SPLITS

Date Ratio
02 Nov 20121-9
02 Jul 20091-100